JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 15, 2008; DOI: 10.1124/jpet.108.144717


0022-3565/09/3281-351-361$20.00
JPET 328:351-361, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.144717v1
328/1/351    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Godlewski, G.
Right arrow Articles by Kunos, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Godlewski, G.
Right arrow Articles by Kunos, G.

CARDIOVASCULAR

The Endogenous Brain Constituent N-Arachidonoyl L-Serine Is an Activator of Large Conductance Ca2+-Activated K+ Channels

Grzegorz Godlewski, László Offertáler, Douglas Osei-Hyiaman, Fong Ming Mo, Judith Harvey-White, Jie Liu, Margaret I. Davis, Li Zhang, Raj K. Razdan, Garry Milman, Pal Pacher, Partha Mukhopadhyay, David M. Lovinger, and George Kunos

Laboratories of Physiologic Studies (G.G., L.O., D.O.-H., F.M.M., J.H.-W., J.L., P.P., P.M., G.K.) and Integrative Neuroscience (M.I.D., L.Z., D.M.L.), National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland; Organix, Inc., Woburn, Massachusetts (R.K.R.); and Department of Medicinal Chemistry, Hebrew University, Jerusalem, Israel (G.M.)

The novel endocannabinoid-like lipid N-arachidonoyl L-serine (ARA-S) causes vasodilation through both endothelium-dependent and -independent mechanisms. We have analyzed the vasorelaxant effect of ARA-S in isolated vascular preparations and its effects on Ca2+-activated K+ currents in human embryonic kidney cells stably transfected with the {alpha}-subunit of the human, large conductance Ca+-activated K+ (BKCa) channel [human embryonic kidney (HEK) 293hSlo cells]. ARA-S caused relaxation of rat isolated, intact and denuded, small mesenteric arteries preconstricted with (R)-(-)-1-(3-hydroxyphenyl)-2-methylaminoethanol hydrochloride (pEC50, 5.49 and 5.14, respectively), whereas it caused further contraction of vessels preconstricted with KCl (pEC50, 5.48 and 4.82, respectively). Vasorelaxation by ARA-S was inhibited by 100 nM iberiotoxin. In human embryonic kidney cells stably transfected with the {alpha}-subunit of the human BKCa channel cells, ARA-S and its enantiomer, N-arachidonoyl-D-serine, enhanced the whole-cell outward K+ current with similar potency (pEC50, 5.63 and 5.32, respectively). The potentiation was not altered by the β1 subunit or mediated by ARA-S metabolites, stimulation of known cannabinoid receptors, G proteins, protein kinases, or Ca2+-dependent processes; it was lost after patch excision or after membrane cholesterol depletion but was restored after cholesterol reconstitution. BKCa currents were also enhanced by N-arachidonoyl ethanolamide (pEC50, 5.27) but inhibited by another endocannabinoid, O-arachidonoyl ethanolamine (pIC50, 6.35), or by the synthetic cannabinoid O-1918 [(-)-1,3-dimethoxy-2-(3-3,4-trans-p-menthadien-(1,8)-yl)-orcinol] (pIC50, 6.59), which blocks ARA-S-induced vasodilation. We conclude the following. 1) ARA-S directly activates BKCa channels. 2) This interaction does not involve cannabinoid receptors or cytosolic factors but is dependent on the presence of membrane cholesterol. 3) Direct BKCa channel activation probably contributes to the endothelium-independent component of ARA-S-induced mesenteric vasorelaxation. 4) O-1918 is a BKCa channel inhibitor.


Received August 11, 2008; accepted October 7, 2008.

Address correspondence to: Grzegorz Godlewski, National Institute on Alcohol Abuse and Alcoholism, 5625 Fishers Lane, Bethesda, MD 20892-9413. E-mail: godlewskig{at}mail.nih.gov







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.